Spinal muscular atrophy (SMA) is classified according to the age of onset and severity of the clinical manifesta tions into: acute (Werding-Hoffman disease or type I), intermediate (type II) and juvenile (Kugelberg-Wilander disease or type III) forms. All three SMAs have been linked to markers at 5q11.2-q13.3. Two candidate genes deleted in SMA patients are the survival motor neuron (SMN) gene and the neuronal apoptosis inhibitory protein (NAIP) gene. We have performed molecular analyses of these genes in 30 unrelated Macedonian families (17 with type I, eight with type II and five with type III forms of the disease). Deletions of exons 7 and 8 of the SMN gene were found in 76.6% (23/30) of patients (94.1% in type I, 87.5% in type II). Among these 23 families, 19 had both exons deleted, while four had deletions only of exon 7. Deletions of exon 5 of the NAIP gene were found in 41.2% (7/17) patients with type I SMA and in 12.5% (1/8) of patients with type II SMA. No deletions of the SMN gene were found in 30 parents and 30 normal controls. We found 2/30 (6.7%) parents to be homozygous for the dele tion of exon 5. Our data support the hypothesis that the telomeric SMN gene plays a major role in determining the clinical course of the disease, while the defects in the NAIP gene have only a modifying effect on the phenotype.
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INTRODUCTION
Spinal muscular atrophy (SMA) is the second most common autosomal recessive disorder, with an overall incidence of about 1 in 6,000 to 10,000 live births and a carrier frequency of about 1/40 [1] . The disease is charac terized by degeneration of the a-motor neurons of the anterior horns of the spinal cord, which leads to progres sive symmetrical weakness and wasting in the proximal muscles. Three types of SMA have been distinguished on the basis of clinical severity and age of onset: type I (Warding-Hoffman disease) is the most severe form with clinical onset generally before the age of 6 months. Affected individuals cannot sit unaided and death usually occurs before the age of 2 years; type II is an intermediate form characterized by early onset, inability to walk and usually survive beyond the age of 10 years; type III (Kugelberg-Vilander disease), is the mild form being char acterized by late age at onset and variable clinical severity. Affected individuals are able to walk independently and may have a normal life expectancy [2] .
All three forms of SMA have been linked to markers at 5q11.2-q13.3 [3, 4] . Deletional events within this region have been associated with SMA, and two candidate genes within this region identified: the survival motor neuron (SMN) and neuronal apoptosis inhibitory protein (NAIP) genes [5] [6] [7] [8] [9] . This region of the genome is inherently unsta ble, and contains with two almost identical copies of the SMN gene, one centro meric (SMNcen or cBCD541) and one telomeric (SMNtel) and multiple copies of pseudo genes of NAIP [10] . The two copies of the SMN gene differ in sequence by only five nucleotide changes along 20 kb and both are transcribed [9] . It has been reported that most SMA patients (>95%) are homozygous for dele tions of the SMN telomeric copy, but no specific muta tions explaining the three SMA phenotypes have been found [9, 11] . One full NAIP gene and several truncated copies are present in the SMA region. Specific exons of NAIP are deleted in SMA patients and also in 2% of unaf fected carrier individuals. Deletions in the NAIP gene vary in frequency in different populations from 67.9 to 0% and appear to be higher in type I patients than in types II and III [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . The NAIP gene shows similarity with baculoviral genes involved in inhibition of apoptosis in infected insect cells [7] .Thus, loss of the NAIP gene is not suffi cient to cause the disease. The NAIP gene is probably involved in modification of the severity of SMA. Recent studies have shown that a gene conversion event, in which the SMNtel is replaced by its centromeric counterpart (SMNcen), is a common mechanism in the genesis of mild SMA alleles, and an increased number of SMNcen genes may partially compensate for deficiency of SMNtel [19, 20] .
We here present our data on the molecular analysis of the SMN and NAIP genes in patients with SMA from the Republic of Macedonia.
healthy individ uals, were studied. Patients fulfilled the diagnostic criteria defined by the International SMA Consortium [21] .
Molecular Analysis. Genomic DNA was extracted from peripheral blood lymphocytes following standard phenol/chlorophorm procedures [22] . The presence of deletions of exons 7 and 8 of the SMN gene were deter mined from polymerase chain reaction/restriction fragment length polymorphism (PCR/RFLP) analyses [23] . Poly merase chain reaction was carried out in a final volume of 25 mL containing 100 ng of genomic DNA, 20 pmoles of each primer, 200 mM of each dNTP, 1.5 mM MgCl 2 and 1U Taq DNA polymerase (Ampli Taq Gold; Applied Bio Systems, Branchburg, NJ, USA). Sequences of the primers for amplification of SMN exon 7 (R111: 5'-AGA CTA TCA AAC TTA AAT TTC TGA TCA-3' and x-7Dra: 5'-CCT TCC TTC TTT TTG ATT TTG TTT-3') and SMN exon 8 (541C960: 5'-GTA ATA ACC AAA TGC AAT GTG AA-3' and 541C1120: 5'-CTA CAA CAC CCT TCT CAC AG-3') [23] . Samples were subjected to 30 cycles of amplification consisting of 1 min. at 94°C, 1 min. at 57°C and 1 min. at 72°C and a final extension at 72°C for 10 min. The PCR products of SMN exon 7 and SMN exon 8 were digested with 2U of restriction enzymes DraI and DdeI, respectively, at 37°C overnight. Digested products were run on 8% non denaturing acrylamide gel (39:1 Acryla mide/BisAcrylamide) at 30mA for 3 hours in TBE buffer and visualized under UV light after ethidium bro mide staining. The PCR digestion products of exons 7 and 8 of the SMNtel gene and the copy gene can readily be distinguished since the copy gene contains a recognition site for the restriction enzyme (DraI/exon 7 and DdeI/exon 8) and that site is absent in the SMNtel (functional) gene. The SMN/exon 7/DraI digestion in healthy individuals, converged into two fragments to the SMNtel and SMNcen copy. The SMN/exon 8/DraI digestion gave three frag ments: that with a higher molecular weight corresponding to SMNtel, and the rest corresponding to the SMNcen copy. Normal results were indicated by the presence of SMNtel and SMNcen exons 7 and 8 ( Figure 1A and 1B) . The restriction digest method does not differentiate between a true deletion and a gene conversion, but cor rectly determines the absence of SMNtel exons 7 and 8 from their normal genomic position. analyses were carried out as described in (9) . Genomic DNA (100-200 ng) was amplified using exon 7 R111 and 541C770 and exon 8 541C960 and 541C1120 specific oligonucleotide primers. A total of 10 mL of PCR product was mixed with 10 mL 95% formamide, 0, 25% bromphenol blue and 0.25% xylene cyanol. The samples were denatured at 95°C for 5 min. and loaded onto a 12% non denaturing acryl amide gel (39:1 Acrylamide/BisAcrylamide). The gels were run at 15W for 16 hours at 16°C and visualized under UV light or after silver staining (Figure 2) . The results were compared with those from DNA from healthy con trols and from individuals with deletions confirmed by the restriction method.
MATERIALS AND METHODS

Patients
Analysis of the Neuronal Apoptosis Inhibitory
Pro tein Gene. The NAIP gene analysis was performed by multiplex PCR amplification of exons 5 and 13, using primers specific for exon 5 (1863: 5'-CTC TCA GCC TGC TCT TCA GAT-3' and 1864: 5'-AAA GCC TCT GAC GAG AGG ATC-3') and exon 13 (1258: 5'-ATG CTT GGA TCT CTA GAA TGG-3' and 1343: 5'-CCA GCT CCT AGA GAA AGA AGG A-3') as described in [7] . Exon 13 is present in both functional and pseu-dogene copies of NAIP and can therefore be used as a positive PCR control for exon 5 which is present only in the func tional NAIP gene. The PCR was performed using the pro cedure described above, except that the annealing step was carried out for 1 min. at 60°C. Samples were loaded onto a 2% agarose gel containing ethidium bromide, run for 1 hour at 80-100V and visualized under UV light (Figure 3) . SMA. Deletion only in SMNtel exon 8 (genotype F) and in SMNtel exon 8 and exon 5 of NAIP (genotype H) was not found in our samples.
RESULTS
The centromeric copies of exons 7 and 8 were not affected in any of the patients, however, a dele tion of one copy was found in one normal control. The SSCP analysis detected an aberrant fragment indicating a point mutation in exon 7 of the SMNtel gene in one type I patient. Analyses of the Neuronal Apoptosis Inhibitory Protein Gene. Deletion of exon 5 of the NAIP gene was found in 41.2% (7/17) type I patients and in one type II patient (1/8). Only two of 30 parents (6.7%) were found to be homozygous for the NAIP exon 5 deletion. No dele tions of the NAIP exon 5 were found in 30 normal con trols.
Correlation Analyses of Survival Motor Neuron and Neuronal Apoptosis Inhibitory Protein Gene Dele tions. In order to correlate the extent of the deletion with clinical severity of disease, we have analyzed the deletion pattern of both genes. We have constructed genotypes of patients using the model proposed in [24] . The results are shown in Table  1 . Genotype A, which represents a large deletion, including telomeric SMN exons 7 and 8 and also NAIP, has a higher incidence in type I SMA patients Our study of the molecular basis of SMA showed a frequency for SMN gene deletions in Macedonian patients of 77.0% (94.1% in type I, 87.5% in type II). Deletions involving both exons 7 and 8 (82.6%) was much more frequent than deletions of exon 7 only (17.4%). Our data support the hypothesis that the telomeric SMN gene may play a major role in determin-ing the clinical severety of SMA [11] [12] [13] [14] [15] [16] [17] [18] [26] [27] [28] [29] [30] . Deletion of exon 5 of the NAIP gene was detected in 27.0% of SMA patients and in 6.7% par ents. A higher frequency of deletions in the NAIP gene was found in SMA type I (41.2%) than SMA type II (11.1%) patients. Deletion in exon 5 of NAIP, which is specific for the functional NAIP gene, shows wide frequency variation (0-67%) in different population studies [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19, 20] . Deletions of one or both of exon 5 of the NAIP gene is not sufficient to cause the disease. Patients with no detectable deletion in exons 7 and 8 of the SMN gene could be due to deletions or point mutations in the promotor or in exons under investiga-tion or could not be identified under these analytical condi tions. In summary, our data confirm the view that SMA is associated with a high frequency of deletions in the 5q13 chromosome region, and indicate that the more severe phenotype is associated with more extensive deletions. They also support the hypothesis that the telomeric SMN gene may play a major role in determining the clinical severity of SMA, while the NAIP gene has a modifying effect on the phenotype. Deletion screening in exons 7 and 8 of the SMNtel gene has become an important diagnostic tool in infantile SMA. DNA analysis is useful in confirm ing the clinical diagnosis of SMA and for prenatal predic tion in SMA families.
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